IC
RNAC icon

Ikarian Capital’s Cartesian Therapeutics RNAC Stock Holding History

Ikarian Capital’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$128K Hold
20,807
– – 0.01% 146
2025
Q4 		$150K Sell
20,807
-1,359
-6% -$11K 0.01% 158
2025
Q3 		$227K Hold
22,166
– – 0.02% 150
2025
Q2 		$230K Hold
22,166
– – 0.04% 108
2025
Q1 		$292K Sell
22,166
-30,000
-58% -$536K 0.04% 130
2024
Q4 		$934K Sell
52,166
-27
-0.1% -$547 0.13% 111
2024
Q3 		$841K Sell
52,193
-190,177
-78% -$2.97M 0.12% 103
2024
Q2 		$6.55M Buy
+242,370
New +$5.78M 1.14% 26

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital's RNAC Position: Q1 2026 in Review

Ikarian Capital held its Cartesian Therapeutics (RNAC) position steady in Q1 2026 at 20,807 shares worth $128K. The position accounts for 0.01% of the portfolio, ranked #146.

Ikarian Capital first reported a position in RNAC in Q2 2024 and has held it in 8 quarters since. The position peaked at $6.55M in Q2 2024. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Ikarian Capital held 20,807 shares of Cartesian Therapeutics worth $128K as of Q1 2026.
  • Ikarian Capital left its Cartesian Therapeutics share count unchanged in Q1 2026.
  • Cartesian Therapeutics made up 0.01% of Ikarian Capital's portfolio in Q1 2026, its #146 holding.
  • Ikarian Capital first reported a position in Cartesian Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Ikarian Capital's Cartesian Therapeutics position peaked at $6.55M in Q2 2024.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.